MGMT and glioblastoma: The findings of these studies are thought-provoking and provide evidence to suggest that the combination therapy of lomustine and temozolomide may enhance survival rates when compared to standard temozolomide treatment in a specific subgroup of younger, healthy patients with MGMT-methylated glioblastoma.